INTRODUCTION
============

All neural function results from a series of electrical and chemical signals. The two realms of signaling are often bridged within neurons by voltage-gated Ca^2+^ channels, such as N channels ([@bib76]). With depolarization of postsynaptic sites, N-channel activity (N current) triggers biochemical changes, including modulation of certain ion channels ([@bib77]), enzyme activation ([@bib58]), and gene transcription ([@bib8]; [@bib76]; [@bib83]). In turn, G~q~ protein-coupled receptors (PCRs) converge on several signal transduction cascades to modulate the N channel\'s response to changing membrane potential. Some of these pathways are well described, so both signaling molecules and sites of modulation on N channels are known ([@bib68]).

A notable exception is the M~1~ receptor (M~1~R), a G~q~PCR that modulates postsynaptic N current by an incompletely described signaling cascade referred to as the slow pathway ([@bib5]; [@bib43]). Other transmitters such as substance P (SP), the natural ligand for the neurokinin-1 receptor (NK-1R), also modulate N current by a slow pathway ([@bib63]; [@bib27]) that couples to G~q~ ([@bib42]), suggesting that multiple G~q~PCRs converge on this pathway ([@bib68]). Recent studies propose that a reduction in phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P~2~) levels during G~q~PCR stimulation suffices for inhibition ([@bib79]; [@bib21]; [@bib46]). In this model, channels are available to open when PtdIns(4,5)P~2~ associates with them. During muscarinic stimulation, PtdIns(4,5)P~2~ is depleted from the membrane, creating a concentration gradient that favors PtdIns(4,5)P~2~ dissociating and diffusing away from channels. This model appeals to many in part because PtdIns(4,5)P~2~ dissociation and depletion have been established as the mechanism that inhibits M current, a voltage-gated K^+^ current ([@bib67], [@bib69]; [@bib19]; [@bib70]).

However, our previous studies with superior cervical ganglion (SCG) neurons indicate that modulation of native N current by M~1~Rs requires events downstream of PtdIns(4,5)P~2~ hydrolysis ([@bib35]; [@bib39], [@bib84]). We found that the muscarinic agonist oxotremorine-M (Oxo-M) and arachidonic acid (AA) elicit the same distinct pattern of modulation ([@bib37]; [@bib35]), not only inhibiting N current at positive test potentials but also enhancing N current at negative test potentials ([Fig. 1 A](#fig1){ref-type="fig"}). Enhancement and inhibition by AA occur at distinct sites and exhibit different biophysical characteristics ([@bib4]; [@bib37]). Moreover, M~1~R stimulation releases AA in central and SCG neurons ([@bib74]; [@bib40]). In contrast, only minimal fatty acid release occurs after muscarinic stimulation in SCG neurons lacking group IVa PLA~2~([@bib40]). Consistent with the need for PtdIns(4,5)P~2~metabolites, inhibiting AA release from phospholipids by antagonizing PLA~2~ activity or including BSA, a scavenger of AA ([@bib66]), in the bath solution minimizes N-current modulation by Oxo-M ([@bib35]; [@bib38], [@bib39]), suggesting that AA may be a second messenger of the slow pathway.

At present, no binding site for either PtdIns(4,5)P~2~ or AA on N channels has been determined. Moreover, whether the sites that confer AA sensitivity reside in the same channel or whether two distinct channel populations mediate enhancement and inhibition remains untested. Therefore, we attempted to use the power of mutagenesis to separate enhancement from inhibition in human embryonic kidney 293 (HEK-293) cells expressing recombinant M~1~Rs and N channels. N channels are multimeric complexes defined by a large pore-forming subunit (Ca~V~2.2) that associates with ancillary α~2~δ and Ca~V~β subunits ([@bib9]). We made the serendipitous discovery that enhancement and inhibition separate without mutagenesis simply by expressing different wild-type Ca~V~βs.

![M~1~R-induced inhibition of recombinant N current is blocked by a PLA~2~ antagonist. HEK-M1 cells were transiently transfected with N-channel subunits Ca~V~2.2, α~2~δ -1, and Ca~V~β3. (A) Working model of the slow pathway in which AA release, catalyzed by PLA~2~, is a necessary component to elicit N-current modulation. AA enhances current (green arrow) by acting at a distinct site that may be extracellular or in the outer leaflet of the membrane ([@bib4]). AA inhibits N current by acting at an intracellular site or a site within the inner leaflet ([@bib4]; [@bib37]). (B) Summary of the percent change in mean current amplitude in tsA 201 cells after 1-min exposure to 10 µM Oxo-M or in HEK-M1 cells in the presence or absence of 10 µM OPC, a PLA~2~ antagonist. Error bars represent SEM. (C) Time course of peak inward current using 5 mM Ba^2+^ as charge carrier before, during, and after bath application of 10 µM Oxo-M. (D) Representative whole-cell current traces selected from the respective time course before (black) and 1 min after (red) Oxo-M application. Currents were elicited every 4 s by stepping to a test potential of 0 mV for 100 ms. (E and F) Modulation of N current from tsA 201 cells stably transfected with Ca~V~2.2, α~2~δ-1, and Ca~V~β3 and transiently transfected with 500--1,000 ng/well of M~1~Rs. eGFP is shown in the time course and representative sweeps. The charge carrier was increased to 20 mM Ba^2+^ to improve the signal to noise ratio, and accordingly the test potential was adjusted to 10 mV. (G and H) HEK-M1 cells were transiently transfected with N-channel subunits Ca~V~2.2, α~2~δ-1, and Ca~V~β2a. Modulation of N current by M~1~R stimulation illustrated in a time course (G) and current traces (H). (I and J) N-current modulation from cells expressing HEK-M1 cells transfected as for C. Cells were exposed to OPC for at least 3 min before application of Oxo-M. Bars, 0.4 nA.](JGP_200910203_RGB_Fig1){#fig1}

MATERIALS AND METHODS
=====================

Transfection of HEK-M1 cells
----------------------------

HEK-293 cells with a stably transfected M~1~R (HEK-M1; [@bib50]), a gift from E. Liman (University of Southern California, Los Angeles, CA), were cultured in Dulbecco\'s modified Eagle\'s medium/F12 (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 1% G418 (geneticin-selective antibiotic, nonsterile; Invitrogen), and 1% HT supplement (Invitrogen). Cells were transferred into 12-well plates for transfection. Recombinant cells at 50--80% confluence were transfected for 1 h with Ca~V~2.2 e(Δ24a, +31a, +37b), the N-channel variant found in SCG neurons ([@bib31]); α~2~δ-1, which is also expressed in SCG ([@bib32]); and various Ca~V~βs at a 1:1:1 or 1:1:2 molar ratio along with enhanced green fluorescent protein (eGFP) at ∼10% of the total DNA using Lipofectamine and PLUS reagent (Invitrogen) as per the manufacturer\'s instructions. Where noted, the transfection mixture contained expression plasmids encoding 0.028 µg/well NK-1R (UMR cDNA Resource Center, University of Missouri, Rolla, MO). 500--1,000 ng total DNA was transfected per well. 24--48 h after transfection, cells were replated on poly-[l]{.smallcaps}-lysine--coated coverslips and allowed to settle for at least 1 h before recording. tsA 201 cells stably transfected with Ca~V~2.2, α~2~δ1, and Ca~V~β3 were provided by D. Lipscombe (Brown University, Providence, RI). These cells were transfected with 500--1,000 ng per well of the M~1~R (a gift from N. Nathanson, University of Washington, Seattle, WA) along with eGFP at 10% of the total DNA and processed as described above for current recordings.

Ca~V~β1b (GenBank/EMBL/DDBJ accession no. [X61394](X61394)), Ca~V~β2a (GenBank accession no. [M80545](M80545)), and Ca~V~β4 (GenBank accession no. [L02315](L02315)) were provided by E. Perez-Reyes (University of Virginia, Charlottesville, VA); Ca~V~2.2 (GenBank accession no. [AF055477](AF055477)), α~2~δ-1 (GenBank accession no. [AF286488](AF286488)), and Ca~V~β~3~ (GenBank accession no. [M88751](M88751)) were provided by D. Lipscombe. The Ca~V~β2a(C3,4S) mutant was provided by A. Fox (University of Chicago, Chicago, IL); Ca~V~β2aβ3 and Ca~V~β2aβ1b chimeras were provided by R. Ten Eick (Northwestern University, Evanston, IL). The mutant and chimeric Ca~V~βs were originally made in M. Hosey\'s laboratory (Northwestern University; [@bib12], [@bib13]; [@bib11]). Recordings from untransfected HEK-M1 cells yielded whole-cell currents of 9.0 ± 1.3 pA in 20 mM Ba^2+^ (Roberts-Crowley, M., personal communication). To avoid spurious results from endogenous currents, any transfected cells having less than −150 pA were discarded.

Preparation of neonatal rat SCG neurons for electrophysiology
-------------------------------------------------------------

Dissociated sympathetic neurons were obtained from SCG of 1--4-d-old Sprague-Dawley rats (Charles River) according to the methods of Liu and co-workers ([@bib37]; [@bib35]). To isolate the actions of the slow pathway on N-type current, cells were incubated for at least 5 h with 500 ng/ml pertussis toxin (Biological Laboratories, Inc.) before initiating whole-cell recording experiments ([@bib6]). Also, bath solutions included 1 µM of the L-type Ca^2+^ channel antagonist nimodipine to minimize the small amount of L-type current present in SCG neurons. Cells were used within 12 h to avoid recording from cells with processes.

Electrophysiology
-----------------

Ba^2+^ currents were recorded at room temperature (20--24°C) using the whole-cell configuration of a model 3900a (Dagan), Axon 200A, or Axon 200B (MDS Analytical Technologies) patch-clamp amplifier using methods that were described previously ([@bib4]; [@bib37]). Currents were filtered at 5 kHz using the amplifier\'s four-pole low-pass Bessel filter and were digitized at 20 kHz with a micro1401 interface (Cambridge Electronic Design \[CED\]). Data were collected using Patch 6.4 or Signal 2.15 software suites (CED) and stored on a personal computer. Before analysis, capacitive and leak currents were subtracted using a scaled-up current elicited with a test pulse to −100 mV. Pipette resistance ranged from 2.5 to 5 MΩ. Ba^2+^ currents were elicited every 4 s by stepping from −90 to 0 mV for 100 ms unless otherwise noted. For cells expressing Ca~V~β2a, 20 mM Ba^2+^ was used as the charge carrier to improve the signal to noise ratio. The internal solution contained 135 mM Cs-Asp, 10 mM HEPES, 0.1 mM 1,2-bis(*O*-aminophenoxy)ethane-*N*,*N*,*N*',*N*'-tetraacetic acid (BAPTA), 5 mM MgCl~2~, 4 mM ATP, and 0.4 mM GTP, adjusted to pH 7.5 with CsOH. The external solution contained 135 mM *N*-methyl-[d]{.smallcaps}-glutamine-aspartate, 10 mM HEPES, and 5 or 20 mM Ba^2+^ (as indicated), adjusted to pH 7.5 with CsOH. 135 mM *N*-methyl-[d]{.smallcaps}-glutamine-aspartate was substituted for Ba^2+^ when its concentration was lowered from 20 to 5 mM.

Pharmacological agents
----------------------

Oxo-M (Tocris Biosciences, Inc.) was prepared as a stock solution in double-distilled water and was diluted 1,000 times with bath solution. SP was prepared as a stock solution in 0.05 M acetic acid and diluted at least 2,000 times with bath solution. AA (Nu-Chek Prep), oleyloxyethyl phosphorylcholine (OPC; EMD), and nimodipine were prepared as stock solutions made up in 100% ethanol and diluted 1,000 times with bath solution. All chemicals were obtained from Sigma-Aldrich except where noted.

Data analysis
-------------

The Patch 6.4 and Signal 2.15 software were used to measure peak inward current of whole-cell traces. A trough-seeking function was used to determine peak current where indicated. Data were further analyzed using Excel (Microsoft) and Origin 7.0 (OriginLab). Percent inhibition was calculated as \[(I − I')/I\] × 100, where I is the control current amplitude determined by a mean of five whole-cell current measurements before application of a particular agent and I' is the mean of five current measurements at the time specified for the determination. Conductance was calculated from a modified Ohm\'s law equation, G = I/(V~m~− V~rev~), where I is the peak current at each test potential, V~m~ is the test potential, and V~rev~ is the apparent reversal potential. Relative conductance curves, (G/G~max~) − voltage (V~m~), were plotted for whole-cell currents before and after AA. Data were curve fit using the Boltzmann equation function in Origin 7.0, yielding a curve fitting the equation G/G~max~ = G~max~ + (G~min~ − G~max~)/(1 + exp\[(V~m~ − V~m~1/2)/k)\], where G~max~ is the maximal conductance, G~min~ is the minimal conductance, V~m~ is the test potential, V~m~1/2 is the voltage at half-maximal conductance, and k is the slope factor.

Immunocytochemistry of Ca~V~β subunits
--------------------------------------

Adult SCG neurons were plated on chamber slides (Nagle Nune International), treated with poly-[l]{.smallcaps}-lysine, and cultured overnight. Cells were washed with PBS twice for 5 min and fixed with 100% acetone for 10 min. The fixative was washed away with PBS at room temperature three times for 5 min. Cells were then exposed to PBS containing 10% normal goat serum for 60 min at room temperature followed by incubation with primary antibody for 60 min at room temperature. Mouse anti-Ca~V~β2 (NeuroMab), rabbit anti-Cavβ3 (Sigma-Aldrich), and mouse anti-Cavβ4 (NeuroMab) were diluted 1:1,000 in Antibody Diluent (Dako). Thereafter, cells were washed with PBS three times for 5 min and were incubated for 60 min in the dark at room temperature with Alexa Fluor 488 anti--mouse antibody or Alexa Fluor 488 anti--rabbit antibody (Invitrogen) diluted 1:200 in Antibody Diluent. After incubation with secondary antibodies, cells were washed with PBS three times for 5 min. A second fixation was performed. Slides were then washed with distilled water and covered with the aqueous mounting medium Prolong Gold Antifade reagent (Invitrogen). Images of immunofluorescence were obtained at room temperature using a custom-built, video-rate confocal microscope ([@bib61]) with a 40× objective lens. An excitation wavelength of 488 nm was used, and emission spectra were collected with long-pass filters (OGSIS) at 515 nm ([@bib51]).

RT-PCR of Ca~V~β subunits
-------------------------

Homogenized tissue samples were lysed in 0.8 ml TRIZOL reagent (Invitrogen), and DNA was removed from RNA using phenol-chloroform phase separation. Next, RNA was precipitated using isopropyl alcohol and washed with 75% ethanol. After drying, the RNA pellet was dissolved in RNase-free water. Subsequently, reverse transcription was performed using 1.0 µl of 10× buffer reverse transcriptase, 1.0 µl deoxyribonucleotide triphosphate (dNTP) mix (5 mM each of dNTP), 1.0 µl oligo-dT primer (0.5 mg/ml), 0.125 µl RNase inhibitor (40 U/µl; Promega), 0.5 µl Omniscript Reverse transcription, and RNase-free water to make up a total volume of 10 µl (all reagents were obtained from QIAGEN unless otherwise noted). The mixture was incubated at 37°C for 1 h and heated at 93°C for 5 min followed by cooling on ice to rapidly inactivate the transcriptase. Aliquots of reverse transcription PCR product were amplified by PCR using the primers Ca~V~β2a (5′-ATAACCACAGAGAGGAGAGCCACA-3′ and 5′-TATACATCCCTGTTCCACTCGCCA-3′; 258-bp product) and Ca~V~β3 (5′-TCCCTGGACTTCAGAACCAGCAG-3′ and 5′-TTGTGGTCATGCTCCGAGTCCTG-3′; 368 bp; [@bib30]). Reaction mixtures for PCR contained 2 µl of template cDNA, 2.5 µl of 10× buffer, 0.5 µl dNTP mix, and 2 µl each of forward and reverse primer and were made up in distilled water to a final volume of 25 µl. The protocol for amplification was 94°C for 4 min followed by 33 cycles of 94°C for 45 s, 60°C for 45 s, 72°C for 1 min, and holding at 72°C for 10 min for last extension. PCR products were run on 1.8% agarose gel stained with ethidium bromide along with a 1,000-bp DNA ladder (Fermentas Life Sciences).

Statistical analysis
--------------------

Summary data are presented as means ± SEM. A two-tailed paired *t* test was used to determine differences between control and agonist. For comparisons of two different groups, data were analyzed by a two-tailed Student\'s *t* test for two means. For multiple comparisons, statistical significance was determined using Origin 7.0 by a one-way ANOVA followed by a Tukey multiple comparison posthoc test. Statistical significance was set at P ≤ 0.05.

Online supplemental material
----------------------------

Fig. S1 shows that exogenous application of AA inhibits N-type current in SCG neurons. The L-type channel agonist FPL 64176 was used to distinguish effects of AA on N current from L current. The AA analogue ETYA (5,8,11,14-eicosatetraynoic acid) was used to block metabolism of AA. Fig. S2 demonstrates that the enhancing and inhibiting effects of AA are reversible using an application of fatty acid--free BSA subsequent to AA application. Fig. S3 shows that in HEK-M1 cells transfected with Ca~V~2.2, α~2~δ-1, Ca~V~β2a, and Ca~V~β3, both enhancement and inhibition of N current occurs during application of AA. Online supplemental material is available at <http://www.jgp.org/cgi/content/full/jgp.200910203/DC1>.

RESULTS
=======

To test whether a homogeneous population of N channels recapitulates both enhancement and inhibition, N currents were screened for modulation by Oxo-M. Recombinant currents were evoked from HEK-M1 cells transiently transfected with N-channel subunits Ca~V~2.2, α~2~δ-1, and Ca~V~β3, which most commonly associates with Ca~V~2.2 ([@bib78]). Oxo-M rapidly inhibited peak inward current, reaching a stable inhibition within 90 s ([Fig. 1, B--D](#fig1){ref-type="fig"}). Because N-current enhancement is voltage dependent ([@bib35]), we compared current--voltage (I-V) plots measured before and after Oxo-M, expecting to observe current enhancement at negative test potentials. However, Oxo-M inhibited current at virtually all voltages ([Fig. 2 C](#fig2){ref-type="fig"}). tsA 201 cells stably transfected with the same subunits exhibited a similar profile of inhibition after exposure to Oxo-M ([Fig. 1, B, E, and F](#fig1){ref-type="fig"}), ruling out a system-specific effect.

![Ca~V~β determines N-current modulation by G~q~PCRs and AA. (A--D) HEK-M1 cells were transiently transfected with Ca~V~2.2, α~2~δ-1, and various Ca~V~β subunits. Currents, measured in 5 mM \[Ba^2+^\], were elicited every 4 s by stepping from −90 to 0 mV for 100 ms unless otherwise noted. Representative whole-cell current traces were always taken before (black) and 3 min after (red) drug application. Averaged normalized I-V plots were taken before (black closed circles) and 90 s after (red open circles) agonist application. *n* = 3--6 cells per group. For cells expressing Ca~V~β2a, 20 mM \[Ba^2+^\] was used as charge carrier to improve the signal to noise ratio. The test potential was adjusted to 10 mV to correct for the shift in peak inward current. (E) Histogram summarizing N-current modulation after 3 min of 10 µM Oxo-M (gray bars) and 5 nM SP (black bars). Percent change in current amplitude was highly significant between Ca~V~β2a and Ca~V~β1b, Ca~V~β3, or Ca~V~β4 irrespective of whether Oxo-M or SP was applied (\*\*, P \< 0.005; one-way ANOVA). (F--I) Modulation of N current by 10 µM AA shown as current traces and averaged I-V plots (*n* = 4--5 cells per group). (J) Histogram summarizing N-current modulation after 3 min of AA (\*\*, P \< 0.005; one-way ANOVA). Error bars represent SEM. Bars, 0.4 nA.](JGP_200910203R_RGB_Fig2){#fig2}

Ca~V~β subunit controls N-current modulation by G~q~PCRs
--------------------------------------------------------

Lack of enhancement at any potential indicated the recombinant system was fundamentally different from N-current modulation observed in SCG neurons. In addition to incomplete recapitulation of G~q~PCR modulation, recombinant N current exhibited robust, fast inactivation ([Fig. 1, D and F](#fig1){ref-type="fig"}, and [Fig. 2 C](#fig2){ref-type="fig"}) as previously observed with channels containing Ca~V~β3 ([@bib48]). In contrast, native N current in SCG neurons exhibits kinetics with little inactivation ([@bib54]), similar to recombinant N current from channels containing Ca~V~β2a ([@bib26]; [@bib81]). Moreover, AA robustly inhibits noninactivating current in SCG neurons evoked with a test pulse duration ranging from 20 ([Fig. S1](http://www.jgp.org/cgi/content/full/jgp.200910203/DC1)) to 700 ms ([@bib34]; [@bib37]). Because SCG neurons express Ca~V~β2 mRNA ([@bib30]), we hypothesized that the majority of N current arises from Ca~V~β2a-containing channels. If true, these channels might exhibit both inhibition and enhancement. We found that Oxo-M rapidly inhibited N current from cells expressing Ca~V~β2a. However, unlike Ca~V~β3, initial inhibition gave way to stable enhancement ([Fig. 1, G and H](#fig1){ref-type="fig"}). Moreover, comparison of I-V plots revealed that Oxo-M no longer inhibited current at any potential but enhanced current at negative test potentials ([Fig. 2 B](#fig2){ref-type="fig"}). Although we hypothesized that expression of Ca~V~β2a would elicit enhancement at negative potentials, separation of enhancement from inhibition based on Ca~V~β expression was unanticipated. Therefore, we tested whether other Ca~V~βs would dually modulate N current by repeating the aforementioned experiments with two other neuronal Ca~V~βs: Ca~V~β1b and Ca~V~β4. As with Ca~V~β3, when either Ca~V~β1b ([Fig. 2 A](#fig2){ref-type="fig"}) or Ca~V~β4 ([Fig. 2 D](#fig2){ref-type="fig"}) was expressed, Oxo-M inhibited current at all test potentials, indicating that channels containing Ca~V~β2a exhibit unique N-current modulation by M~1~Rs.

To determine whether M~1~Rs uniquely influence the profile of modulation, we examined whether N-current modulation by another G~q~PCR depends on Ca~V~β. We tested NK-1Rs because in SCG neurons, stimulation of M~1~Rs and NK-1Rs inhibits N current through converging signaling pathways that require Gα~q~ and downstream activation of PLC ([@bib64]; [@bib27]; [@bib35]). We examined current modulation that occurred after exposure to SP. As with Oxo-M, an initial transient inhibition progressed to a stable current enhancement when Ca~V~β2a was expressed along with Ca~V~2.2 and α~2~δ-1 ([Fig. 3, A and C](#fig3){ref-type="fig"}). In contrast, SP elicited sustained inhibition with Ca~V~β3 expression ([Fig. 2 E](#fig2){ref-type="fig"} and [Fig. 3, B and C](#fig3){ref-type="fig"}). These data indicate that control of modulation by Ca~V~β is a mechanism used by other G~q~PCRs rather than being unique to M~1~Rs ([Fig. 1 A](#fig1){ref-type="fig"}).

![NK-1R stimulation elicits a similar profile of N-current modulation as M~1~Rs. (A and B) HEK-M1 cells were transiently transfected with the NK-1R along with Ca~V~2.2, α~2~δ-1, and either Ca~V~β2a (A) or Ca~V~β3 (B). Using 5 nM SP as the agonist, current modulation is shown in a time course of peak current (left), representative whole-cell current traces (middle), and averaged I-V plots (right; *n* = 4). Bars, 0.4 nA. (C) Summary of the modulatory effects of SP on currents from cells expressing either Ca~V~β2a or Ca~V~β3 (\*\*\*, P \< 0.005; one-way ANOVA). No significant difference in current inhibition was observed from cells expressing Ca~V~β3 with 5 and 250 nM SP (P \> 0.26). Error bars represent SEM.](JGP_200910203_RGB_Fig3){#fig3}

AA elicits a profile of N-current modulation similar to G~q~PCR stimulation
---------------------------------------------------------------------------

AA mimics N-current modulation by M~1~Rs in SCG neurons and may serve as a downstream messenger of this pathway ([@bib35]). If so, AA also should inhibit or enhance recombinant N current similarly to M~1~R or NK-1R stimulation. When this hypothesis was tested, AA\'s actions recapitulated the pattern of modulation observed with M~1~R or NK-1R stimulation: enhancement and inhibition separated based on Ca~V~β expression ([Fig. 2, F--J](#fig2){ref-type="fig"}). If elevated AA levels mediate enhancement and inhibition, both should reverse after washout of exogenous AA. As with SCG neurons, washing with copious amounts of bath solution or with 1 mg/ml BSA reversed modulation ([Fig. S2, A--F](http://www.jgp.org/cgi/content/full/jgp.200910203/DC1)). Moreover, enhancement recurred with a second application of AA after washing with BSA (Fig. S2 A). These findings corroborate our assertion that AA mediates N-current modulation by the slow pathway ([@bib35],[@bib36]; [@bib39]).

As a final test of AA\'s role in the slow pathway, we antagonized endogenous AA\'s release from membrane phospholipids using the PLA~2~ antagonist OPC. Exposure to Oxo-M for 60 s significantly inhibited N current from Ca~V~β3-containing channels (P \< 0.05; *n* = 16). In contrast, OPC eliminated significant current inhibition by Oxo-M (P \> 0.05; *n* = 7; [Fig. 1, B, I, and J](#fig1){ref-type="fig"}). A similar profile was observed with SP (not depicted). The striking recapitulation by AA of G~q~PCR-induced N-current enhancement and inhibition, coupled with the loss of modulation when antagonizing AA release or sequestering free AA with BSA, advance our previous hypothesis that PLA~2~ and AA participate in the slow pathway ([@bib35],[@bib36]; [@bib39]).

Expression of multiple Ca~V~β isoforms produces heterogeneous N currents
------------------------------------------------------------------------

Our findings yield a possible explanation for why SCG neurons exhibit both enhancement and inhibition of whole-cell N current ([@bib4]; [@bib35]; [@bib39]). N current\'s diverse biophysical properties in different neurons have been attributed to Ca~V~2.2 coexpression with different Ca~V~β isoforms within individual neurons ([@bib62]). Similarly, SCG neurons may exhibit both forms of modulation because Ca~V~2.2 coassembles with different Ca~V~βs. If this hypothesis is correct, the pattern of modulation observed in SCG neurons should recapitulate in HEK-M1 cells transfected with multiple Ca~V~βs. When cells were transfected with Ca~V~β2a and Ca~V~β3, the I-V plots recapitulated I-V plots from SCG neurons ([@bib35]), with enhancement occurring at negative potentials and inhibition at positive potentials after exogenously applied AA ([Fig. S3](http://www.jgp.org/cgi/content/full/jgp.200910203/DC1)). However, unlike activity from SCG neurons ([@bib37]; [@bib35]), the currents rapidly inactivated. It has been reported that SCG neurons from 4-d-old rat pups express Ca~V~β2a, Ca~V~β3, and Ca~V~β4 mRNA with trace amounts of Ca~V~β1b mRNA ([@bib30]). We verified the presence of Ca~V~β2, Ca~V~β3, and Ca~V~β4 protein in freshly dissociated SCG neurons by immunocytochemistry ([Fig. 4 A](#fig4){ref-type="fig"}). Therefore, we retested for the modulatory response in HEK-M1 cells transfected with varying ratios of Ca~V~β2a-, Ca~V~β3-, and Ca~V~β4-transformed plasmid. Transfection with a mixture of cDNAs in the molar ratio of 10:1:1 for Ca~V~β2a/Ca~V~β3/Ca~V~β4 in a HEK-M1 cell closely recapitulated the N-current kinetics we had previously observed in SCG neurons ([@bib3]; [@bib35]). Application of 10 µM Oxo-M resulted in significant inhibition of currents elicited at test potentials 10--50 mV, with no significant inhibition at lower potentials ([Fig. 4 B](#fig4){ref-type="fig"}). To ensure the transfection mixture is an accurate recapitulation of the SCG neuron, we harvested fresh SCG neurons from neonatal rat pups and tested them using the same experimental conditions as we used for the HEK-M1 cells. We found that application of 10 µM Oxo-M also resulted in significant inhibition of native currents elicited at test potentials 10--50 mV, with no significant change at lower potentials ([Fig. 4 C](#fig4){ref-type="fig"}). These findings suggest that the N current observed in SCG neurons results from heterogeneous expression of different Ca~V~β isoforms with Ca~V~2.2.

![Expression of multiple Ca~V~β subunits in SCG neurons. (A, top) Confocal micrographs of individual SCG neurons. Starting from the left, the neurons were exposed to no antibodies, secondary antibody (anti--mouse Alexa Fluor 488) only, mouse anti-Ca~V~β2 followed by secondary rabbit anti--mouse Alexa Fluor 488, anti-Ca~V~β3 followed by anti--rabbit Alexa Fluor 488, and mouse anti-Ca~V~β2 followed by secondary antibody. (bottom) Corresponding view shown in bright field. Bar, 10 µm. (B) Representative current traces and mean I-V plots taken from HEK-M1 cells transiently transfected with a 12:12:10:1:1 ratio of Ca~V~2.2/α~2~δ-1/Ca~V~β2a/Ca~V~β3/Ca~V~β4; taken before (black) and after (red) 10-µM Oxo-M application (*n* = 6 cells). All currents for the figure were recorded using 20 mM Ba^2+^. \*, P \< 0.05; paired *t* test at each test potential. (C) Current traces and mean I-V plots taken from freshly dissociated SCG neurons before (black) and after (red) application of 10 µM Oxo-M (*n* = 4 neurons). Error bars represent SEM. Bars, 0.4 nA. (D) RT-PCR of SCG and hippocampal (HC) homogenates from three different 7-d-old rats comparing Ca~V~β2a and Ca~V~β3 expression. RNA from animal \#1 generated lanes 1, 4, 7, and 10. RNA from animal \#2 generated lanes 2, 5, 8, and 11. RNA from animal \#3 generated lanes 3, 6, 9, and 12. Lane 13 represents a negative control: RT-PCR reaction without isolated RNA.](JGP_200910203R_RGB_Fig4){#fig4}

The antibody used in the immunocytochemistry experiments recognizes the peptide sequence RSPKPSANSVTSPHSKE (NeuroMab data sheet N8b_1). This sequence exists in Ca~V~β2a, 2b, 2c, 2d, and 2e but not 2f, 2g, or 2h. Because the presence of Ca~V~β2a variant has never been confirmed in rat neonatal SCG neurons, we looked for its presence by RT-PCR using primers designed specifically for Ca~V~β2a. Using tissue from three different animals, we assessed the presence of Ca~V~β2a and Ca~V~β3 in SCG. As a positive control, we used the same three animals to run parallel experiments of Ca~V~β isoform expression in the hippocampus, a region reported to be enriched in Ca~V~β2 ([@bib14]). We found Ca~V~β2a expression in three of three hippocampal samples and in three of three SCG samples. We also found Ca~V~β3 expression in two of three SCG samples but found negligible Ca~V~β3 expression in hippocampal samples.

A model for dual modulation of N current
----------------------------------------

We established a working model for how Ca~V~β2a controls modulation based on previous studies that examined AA\'s mechanism of inhibition of different Ca^2+^ channels ([@bib4]; [@bib37]). Our experiments with SCG neurons demonstrated that current inhibition by AA occurs intracellularly or within the inner leaflet of the membrane. In contrast, enhancement appears located extracellularly or within the outer leaflet of the bilayer ([@bib4]; [@bib37]). Ca~V~β subunits bind to cytoplasmic loops of Ca~V~2.2 ([@bib55]). Thus, we hypothesized that the unique interactions of Ca~V~β2a with Ca~V~2.2 somehow attenuate inhibition. In SCG neurons ([@bib4]; [@bib37]) and with recombinant channels containing either Ca~V~β2a or Ca~V~β3 ([Fig. 5, A and B](#fig5){ref-type="fig"}), AA induces initial N-current enhancement, which is sustained with Ca~V~β2a but for Ca~V~β3 is followed by a more slowly progressing inhibition. This observation supports the model. Thus, we postulated that every Ca~V~2.2 exhibits current enhancement that becomes masked by subsequent, more dominant inhibition.

![Ca~V~β2a blocks N-current inhibition, revealing latent enhancement. (A and B) Time courses of cells expressing either Ca~V~β2a (A) or Ca~V~β3 (B) exposed to AA both exhibit enhancement during the initial phase of time course. However, when Ca~V~β3 is present, inhibition eventually dominates, indicating that both inhibitory and enhancement sites are available for AA to bind. When Ca~V~β2a is present, inhibition no longer occurs, suggesting the palmitoylated Ca~V~β2a occupies the inhibitory site without conferring inhibition. (C and D) Normalized conductance--voltage plots generated from I-V data show a negative shift in G/G~max~ for cells expressing either Ca~V~β2a (C) or Ca~V~β3 (D), indicating that an increased sensitivity to voltage is masked by a dominating inhibition in cells expressing Ca~V~β3. (E) Schematic representation of working model. Upon G~q~PCR stimulation, the released AA binds to both inhibitory and enhancement sites on the channel. When Ca~V~β3 is present, both inhibitory and enhancement sites are available for AA to bind. However, because inhibition dominates, the resultant modulation observed is current inhibition. When Ca~V~β2a is present, inhibition no longer occurs because the palmitoylated Ca~V~β2a occupies the inhibitory site without conferring inhibition. With inhibition antagonized, sustained current enhancement is observed.](JGP_200910203R_RGB_Fig5){#fig5}

Because our previous work indicated that enhancement by AA arises from increased voltage sensitivity ([@bib4]), we compared normalized conductance--voltage (G-V) curves to determine whether increased voltage sensitivity occurs independently of Ca~V~β2a expression. Both Ca~V~β2a- and Ca~V~β3-containing cells exhibited a negative shift in conductance in response to AA ([Fig. 5, C and D](#fig5){ref-type="fig"}), demonstrating that AA increases N-channel voltage sensitivity independently of Ca~V~β subunit expression. These data suggest that Ca~V~β2a\'s unique ability to attenuate inhibition reveals sustained enhancement. In contrast, inhibition results from increased stability of a closed state ([@bib34]), essentially reducing the number of channels available to open. This type of inhibition should dominate an increase in voltage sensitivity; if channels will not open at any voltage, increasing their voltage sensitivity will have little effect on currents. Thus, by blocking a dominating inhibition, Ca~V~β2a unmasks latent enhancement.

Loss of Ca~V~β2a palmitoylation restores partial inhibition of N current by Oxo-M or AA
---------------------------------------------------------------------------------------

Having established that Ca~V~β2a uniquely blocks N-current inhibition by G~q~PCR stimulation or exogenous AA, we investigated the structural aspects of Ca~V~β2a to determine its mechanism of action. A conspicuous feature of Ca~V~β2a is its unique palmitoylation of two cysteine residues near the N terminus ([@bib12]). Our observation that palmitoylated Ca~V~β2a interferes with a fatty acid--mediated inhibition of Ca~V~2.2 raises the possibility of direct antagonism between palmitic acid and AA ([Fig. 5 E](#fig5){ref-type="fig"}). Therefore, we tested a depalmitoylated mutant to determine whether Ca~V~β2a must be palmitoylated to minimize inhibition and reveal enhancement. Currents from channels containing depalmitoylated Ca~V~β2a (Ca~V~β2a\[C3,4S\]; [@bib12]) exhibited an initial transient inhibition after Oxo-M that relaxed, yielding a small but insignificant inhibition ([Fig. 6, A and G](#fig6){ref-type="fig"}). AA initially enhanced current amplitude, followed by significant inhibition ([Fig. 6, B and G](#fig6){ref-type="fig"}). The loss of enhancement and appearance of inhibition, although differing in magnitude with Oxo-M or AA, support the idea that palmitoylation blocks inhibition.

![Palmitoylation determines which form of modulation is observed. (A--F) Using 20 mM Ba^2+^, modulation by Oxo-M or AA of cells expressing mutant Ca~V~β2a(C3,4S) (A and B), Ca~V~β2aβ1b (C and D), or Ca~V~β2aβ3 (E and F) is shown in current traces and I-V plots. Bars, 0.4 nA. (G) Summary of the modulatory effects on currents after application of Oxo-M or AA for 3 min (*n* = 4--7). Error bars represent SEM. (H) Schematic representation of working model.](JGP_200910203R_RGB_Fig6){#fig6}

If palmitoylation is necessary for antagonizing inhibition, palmitoylating another Ca~V~β should convert current inhibition to enhancement. Therefore, we tested a chimera in which the variable N terminus of Ca~V~β1b was replaced with the palmitoylated 16--amino acid N terminus of Ca~V~β2a (Ca~V~β2aβ1b; [@bib13]). In cells expressing Ca~V~β2aβ1b, application of Oxo-M enhanced current with no inhibition ([Fig. 6 G](#fig6){ref-type="fig"}). Moreover, AA no longer inhibited these currents significantly ([Fig. 6 G](#fig6){ref-type="fig"}) compared with Ca~V~β1b (*n* = 4; [Fig. 2 J](#fig2){ref-type="fig"}). The difference in modulation by AA and Oxo-M may be attributed to an exaggerated response to exogenous application of AA compared with the response to physiological concentrations of AA released upon M~1~R stimulation. I-V plots after either Oxo-M or AA exhibited enhancement of current at negative test potentials and no inhibition at positive test potentials ([Fig. 6, C and D](#fig6){ref-type="fig"}), suggesting that the palmitoylated N terminus is both necessary and sufficient to block inhibition.

However, a second chimera in which the N terminus of Ca~V~β3 was replaced with the N terminus of Ca~V~β2a (Ca~V~β2aβ3; [@bib13]) did not block inhibition as effectively. In cells expressing Ca~V~β2aβ3, inhibition by Oxo-M was diminished compared with wild-type Ca~V~β3, whereas AA reversibly inhibited currents similarly to wild-type levels ([Fig. 6, E--G](#fig6){ref-type="fig"}). I-V plots taken before and 90 s after application of Oxo-M or AA exhibited inhibition at positive test potentials ([Fig. 6, E and F](#fig6){ref-type="fig"}). These results indicate that addition of Ca~V~β2a\'s palmitoylated N terminus to Ca~V~β3 only partially reproduced the stable enhancement by Oxo-M or AA normally observed with wild-type Ca~V~β2a. Because Ca~V~β2a protein shares highest sequence homology to Ca~V~β1b ([@bib7]), the simplest interpretation for the varied results with the different chimeras is that that Ca~V~β2aβ1b positions the palmitoylated N terminus so that it minimizes N-current inhibition similarly to wild-type Ca~V~β2a. In contrast, the more divergent Ca~V~β2aβ3 positions the palmitoylated N terminus in a different position relative to Ca~V~2.2 where it is less effective in minimizing inhibition ([Fig. 6 H](#fig6){ref-type="fig"}). In support of this notion, Ca~V~β2aβ3-containing cells exhibited varied kinetics, from noninactivating currents resembling Ca~V~β2a-containing channel activity ([Fig. 2 B](#fig2){ref-type="fig"}) to rapidly inactivating currents resembling depalmitoylated Ca~V~β2a-containing channel activity ([Fig. 6, A and B](#fig6){ref-type="fig"}). Moreover, the kinetics varied within individual recordings and from cell to cell from a rapidly inactivating to a noninactivating kinetic profile (unpublished data). The unstable inactivation kinetics suggests that Ca~V~β2aβ3 cannot dock properly to Ca~V~2.2, thus destabilizing and changing the location of the chimera\'s palmitoyl groups.

Free palmitic acid minimizes N-current inhibition
-------------------------------------------------

If our interpretation that the palmitoyl groups antagonize inhibition is correct, freeing the palmitoyl groups from protein constraints might allow the fatty acids to find and assume their optimal position for blocking inhibition ([Fig. 7 A](#fig7){ref-type="fig"}). Alternatively, if the palmitic acids do not interact directly with Ca~V~2.2, introducing free palmitic acid should not alter N-channel modulation by agonist. We tested this prediction first by preincubating cells expressing NK-1Rs and Ca~V~β3-containing channels with free palmitic acid for at least 8 min. Under these conditions, the sustained inhibition normally observed with SP ([Fig. 7, B and C](#fig7){ref-type="fig"}) was replaced by an initial enhancement that relaxed, resulting in no significant change (P \> 0.24) in current amplitude over time ([Fig. 7, B and D](#fig7){ref-type="fig"}). Moreover, compared with control conditions, little inhibition by SP was detected in I-V plots from cells preincubated with 10 µM palmitic acid ([Fig. 7, C and D](#fig7){ref-type="fig"}). To ensure the block of inhibition was not specific to NK-1Rs, we tested N-current modulation of Ca~V~β3-containing channels in HEK-M1 cells by Oxo-M after a 10-min preincubation with 10 µM palmitic acid. As with SP, free palmitic acid prevented the sustained inhibition observed in its absence, as demonstrated by time courses and I-V plots (compare [Fig. 7, B and E](#fig7){ref-type="fig"} with [Fig. 1, B--F](#fig1){ref-type="fig"} and [Fig. 2, C and E](#fig2){ref-type="fig"}). Bath application of palmitic acid for 8 min did not significantly affect N current (not depicted) when compared with currents recorded under control conditions ([Fig. 7 C](#fig7){ref-type="fig"}), indicating that palmitic acid itself has no modulatory effect. These findings demonstrate that exogenous application of free palmitic acid suffices to block current inhibition of Ca~V~β3-containing N channels. More importantly, these results indicate palmitic acid is both necessary and sufficient to antagonize N-current inhibition during G~q~PCR stimulation ([Fig. 8](#fig8){ref-type="fig"}).

![Palmitic acid antagonizes inhibition of N current by G~q~PCR stimulation. HEK-M1 cells were transiently transfected with NK-1R, Ca~V~2.2, α~2~δ-1, and Ca~V~β3. (A) Diagram showing that preincubation of HEK-M1 cells with exogenously applied palmitic acid blocks inhibition of N channels by fatty acids, such as AA, released after NK-1R or M~1~R activation. (B) Summary showing preincubation of cells with 10 µM palmitic acid (PA) significantly attenuates inhibition by SP or Oxo-M (\*, P \< 0.05 compared with percent change in the absence of palmitic acid). Error bars represent SEM. (C) Modulation of N current by SP from cells expressing Ca~V~β3 is shown in a representative time course, current traces taken before and 3 min after application of SP, and I-V plots (*n* = 5). (D) Preincubation of cells with palmitic acid causes loss of inhibition by SP as shown in a time course, current traces, and I-V plot (*n* = 6). (E) Preincubation of HEK-M1 cells with palmitic acid also causes loss of inhibition by Oxo-M, as shown in a representative time course, current traces, and I-V plots (*n* = 4). Bars, 0.4 nA.](JGP_200910203R_RGB_Fig7){#fig7}

![Model of interference of inhibition by palmitoylated Ca~V~β2a. (A) As presented, our data support a model in which upon G~q~PCR stimulation, release of AA initially enhances N current by acting at a site distinct from inhibition. However, N-current inhibition by AA of channels containing Ca~V~β1b, Ca~V~β3, or Ca~V~β4 dominates modulation of Ca~V~2.2 and obscures enhancement. (B) In the presence of Ca~V~β2a, the palmitoylated N terminus of the Ca~V~β subunit blocks N-current inhibition by endogenously released AA as a result of the two palmitic acids competitively interacting with Ca~V~2.2, thus revealing latent enhancement.](JGP_200910203R_RGB_Fig8){#fig8}

DISCUSSION
==========

In this study, we used a recombinant system to investigate the enhancement and inhibition of N current that occurs during M~1~R stimulation and AA application. In so doing, we made the discovery that the N-channel\'s β subunit directs opposite effects of N-current modulation. Specifically, M~1~R stimulation or exogenous AA uniquely enhanced whole-cell N current from cells expressing Ca~V~β2a but inhibited N current from cells expressing Ca~V~β1b, Ca~V~β3, or Ca~V~β4. This finding allowed us to further examine the modulation of N current and reach several additional conclusions. First, the striking recapitulation of M~1~R-induced modulation by AA, coupled with the loss of modulation when AA release by OPC is blocked, is strong evidence that AA is an integral component of the slow pathway. Second, NK-1R stimulation exhibited a similar dual effect, indicating this unique profile of modulation may be conserved among G~q~PCRs. Third, cells expressing multiple forms of Ca~V~β subunits matched the modulatory profile of SCG neurons under the same recording conditions, implying that the characteristic pattern of modulation observed in SCG neurons results from Ca~V~2.2 coupling with different Ca~V~β isoforms. This finding provides an explanation of how stimulation of M~1~Rs or exogenous AA can elicit both enhancement and inhibition of N current in individual sympathetic neurons ([@bib35]). Fourth, using mutated and chimeric Ca~V~β constructs, we demonstrated that palmitoylation of Ca~V~β2a is a key feature in its capacity to toggle modulation from inhibition to enhancement. Finally, exogenous application of palmitic acid prevented the characteristic N-current modulation by G~q~PCRs, suggesting that Ca~V~β2a\'s palmitoyl groups interfere with a mechanism or mechanisms within the slow pathway.

Increased free AA appears necessary for N-current inhibition by the slow pathway
--------------------------------------------------------------------------------

It is well documented that PtdIns(4,5)P~2~ breakdown by PLC is necessary for slow pathway inhibition ([@bib79]; [@bib35]; [@bib21]; [@bib39]; [@bib15]; [@bib68]); however, whether its breakdown is sufficient for N-current inhibition remains controversial ([@bib79]; [@bib21]; [@bib68]). Our data indicate that fatty acid liberation is both necessary and sufficient to elicit inhibition of Ca~V~2.2 ([@bib4]; [@bib35]; [@bib39], [@bib41]). To demonstrate a role for free AA in N-current inhibition, we used pharmacological agents, the AA scavenger BSA, PLA~2~ antibodies dialyzed internally, and neurons harvested from PLA~2~^−/−^ knockout mice ([@bib35]; [@bib39], [@bib40]). Here we have taken a molecular approach in which expression of palmitoylated Ca~V~β2a provides a highly specific agent to block inhibition by AA, whereas nonpalmitoylated wild-type Ca~V~β subunits conveniently act as negative controls. It must be stressed that none of the findings reported here minimizes PtdIns(4,5)P~2~\'s role but rather documents a requirement for AA in N-current inhibition.

A resolution to the paradox would entail a role for both PtdIns(4,5)P~2~ and AA acting either directly or indirectly on the channel. A model for PtdIns(4,5)P~2~ and AA opposing each other in modulation of K^+^ channels has been published ([@bib49]) in which PtdIns(4,5)P~2~ and AA act at different sites of the channel. Direct competition is possible because AA is an integral piece of the PtdIns(4,5)P~2~ molecule, normally residing in the sn-2 position, and thus could compete for binding to Ca~V~2.2. Although indirect actions of PtdIns(4,5)P~2~ and AA must be considered, as both are bioactive molecules with multiple downstream effects, no requirement for downstream enzymes such as phosphatases or kinases has been found. Moreover, antagonizing enzymes that further metabolize AA have no effect on modulation ([@bib37]; [@bib35]). Nevertheless, increased levels of PtdIns(4,5)P~2~ increase N-channel availability to open, whereas increased levels of AA stabilize N channels in closed and/or inactivated states ([@bib34]; [@bib21]). These opposing effects suggest competition.

A working model for enhancement and inhibition
----------------------------------------------

By exposing SCG neurons to exogenous AA, we characterized N-current enhancement and inhibition as distinct molecular events acting at different sites on N channels. Restriction of AA movement across the cell membrane suggested that enhancement requires AA on the extracellular side or within the outer leaflet, whereas inhibition requires AA on the intracellular side or within the inner leaflet ([@bib4]). These two sites presumably would be equally accessible to AA generated internally because movement of long-chain fatty acids across cell membranes occurs in \<1 s ([@bib23]). Because Ca~V~β subunits are cytoplasmic, we hypothesized that Ca~V~β2a attenuates inhibition without affecting enhancement. In dissociated neurons, AA induces an initial current enhancement followed by a slower progressing inhibition ([@bib4]; [@bib37]). The simplest explanation for these data is that the initial enhancement becomes masked by the subsequent, more dominant, inhibition. Because previous work indicated that enhancement stems from increased voltage sensitivity ([@bib4]), we used normalized G-V curves ([Fig. 5](#fig5){ref-type="fig"}) to show that an increase in voltage sensitivity occurs independently of Ca~V~β2a expression. In contrast, inhibition results from an increase in a slow form of inactivation most likely as a result of increased dwell time in one or more intermediate closed states ([@bib34]). This type of inhibition would essentially reduce the available number of channels providing calcium influx, dominating an enhancement produced by a shift in voltage sensitivity. Thus, by blocking a dominant inhibition, Ca~V~β2a unmasks a latent enhancement. The masking of enhancement offers some explanation for the finding that the majority of studies on N-current modulation have observed inhibition ([@bib18]).

Nevertheless, enhancement and inhibition have been reported from experimental systems similar to the one used here. For example, AA both shifts activation toward negative potentials and simultaneously increases steady-state inactivation of T channels ([@bib72]). Also, in SCG neurons, the amide of AA, anandamide, elicited enhancement at negative potentials and inhibition at positive potentials in I-V plots ([@bib22]). Enhancement marked by a leftward shift in voltage sensitivity was reported for R-type channels in the hippocampus ([@bib71]), a region in which Ca~V~β2 is highly expressed ([@bib14]). Finally, using HEK-293 cells transiently transfected with recombinant M~1~Rs and N channels containing Ca~V~β3, an earlier study showed that carbachol inhibited Ca^2+^ current with no obvious enhancement ([@bib44]). However, I-V curves showed a discernible leftward shift in voltage sensitivity after carbachol.

A new role for palmitoyl groups of palmitoylated proteins
---------------------------------------------------------

Our data identify a previously unrecognized role for protein palmitoylation in which it serves as the key feature of Ca~V~β2a\'s capacity to toggle Ca~V~2.2 modulation from inhibition to enhancement after stimulation of G~q~PCRs. Here and in other systems, palmitoylation targets or anchors proteins to specific membrane domains ([@bib12]; [@bib56]). Although dynamic palmitoylation of Ca~V~β2a has been shown to alter the inactivation kinetics of voltage-gated Ca^2+^ channels in bovine chromaffin cells, the assumed mechanism of action is restriction of movement of channel domains by anchoring the Ca~V~β2a subunit to the membrane ([@bib26]). This anchoring in some way is thought to impede current inactivation ([@bib57]). Thus, palmitoylation increases protein stability and efficiency of action but rarely alters the functional properties of proteins. One exception to this generalization is retinal epithelial protein 65 (RPE65), a chaperone protein for all-trans-retinal esters. In this case, palmitoylation not only targets RPE65 to the plasma membrane but also reverses RPE65\'s binding specificity for vitamin A to all-trans-retinyl ester, consequently affecting how rapidly photoreceptors respond to light ([@bib80]). Thus, palmitoylation qualitatively alters the substrate specificity of the same protein that is reversibly palmitoylated. Here, our data extend the functions of palmitoylation in a new direction by revealing that after stimulation of G~q~PCRs, the palmitoyl groups of one protein, Ca~V~β2a, block inhibition of a second protein, Ca~V~2.2.

Our finding that palmitoylation antagonizes an inhibition mediated by PtdIns(4,5)P~2~ breakdown and increased free AA ([@bib35]; [@bib21]) raises the possibility that dual palmitoyl groups interact directly with Ca~V~2.2 to antagonize AA\'s interaction with Ca~V~2.2 and subsequent inhibition of N-channel activity. The idea that AA may interact directly with Ca^2+^ channels is supported by the finding that M~1~R stimulation or application of exogenous AA also inhibits recombinant Ca~V~3 currents in whole-cell ([@bib82]; [@bib72]; [@bib25]) and ripped-off patch configurations ([@bib10]). Because Ca~V~3 (T type) channels do not require coexpression of Ca~V~β or α~2~δ to open, T-channel inhibition must occur at a site on the pore-forming subunit. Moreover, AA inhibits T current with a Hill coefficient of 1.6, indicating cooperative binding of at least two AA molecules to T channels ([@bib72]). Collectively, these findings are consistent with a direct interaction between AA and T channels. AA likely confers N-current inhibition by acting at a homologous site found on many Ca~V~ channels because native and recombinant Ca~V~1, Ca~V~2, and Ca~V~ 3 channels exhibit similar changes in gating after AA ([@bib65]; [@bib52]; [@bib34]; [@bib75]; [@bib72]; [@bib10]; [@bib33]; [@bib59]).

Palmitoylated Ca~V~β2a may serve as a phospholipid mimic by competing with PtdIns(4,5)P~2~ and free AA for interaction with Ca~V~2.2
------------------------------------------------------------------------------------------------------------------------------------

Under basal conditions, AA normally resides in the sn-2 position of PtdIns(4,5)P~2~. Because palmitoylated Ca~V~β2a appears to antagonize the actions of free AA on Ca~V~2.2, it may also compete with PtdIns(4,5)P~2~ for interaction with Ca~V~2.2, the two palmitic acids of Ca~V~β2a residing in sites normally occupied by the two fatty acid tails of PtdIns(4,5)P~2~. Consistent with its ability to block N-current inhibition by free AA, palmitoylated Ca~V~β2a acts as a phospholipid mimic to maintain normal channel activity ([Fig. 8](#fig8){ref-type="fig"}). This model is attractive in that it incorporates previous models, which propose that PtdIns(4,5)P~2~ associates with channels, increasing their availability to open ([@bib79]; [@bib21]). The model also supports our previous findings ([@bib35]) that increased free AA confers current inhibition either by displacing PtdIns(4,5)P~2~ or by remaining associated with channels after phospholipid breakdown ([@bib60]).

Our findings that free palmitic acid blocks inhibition by SP of Ca~V~β3-containing channels or depalmitoylated Ca~V~β2a-containing channels (see Mitra-Ganguli et al. in this issue) is consistent with the idea that the palmitic acids occupy the same sites recognized by AA. Whether PtdIns(4,5)P~2~ as well as AA compete for the same site of interaction with Ca~V~2.2 as the palmitoyl groups of Ca~V~β2a and where the location of that site is awaits future investigation. However, we have observed that whole-cell recombinant current from Ca~V~β2a-containing channels, in contrast to Ca~V~β3-containing channels ([@bib21]), run down only minimally over time (unpublished data), consistent with palmitoylated Ca~V~β2a functionally substituting for PtdIns(4,5)P~2.~ Thus, when taken together, our findings and the results of other laboratories best fit a model in which palmitoylated Ca~V~β2a, PtdIns(4,5)P~2~, and free AA compete for an overlapping interaction site on Ca~V~2.2. Given the extent that lipids such as PtdIns(4,5)P~2~ and AA associate with membrane protein complexes ([@bib53]; [@bib16]), the interference of such interactions by palmitoylated proteins is predicted to occur in other protein complexes, yielding broad importance beyond ion channel functioning.

Expression of palmitoylated Ca~V~β2a may underlie novel forms of synaptic plasticity
------------------------------------------------------------------------------------

In particular, the presence or absence of palmitoylated Ca~V~β2a may have far-reaching consequences for synaptic plasticity. Ca~V~β2 expression displays an overlapping distribution with G~q~PCRs ([@bib74]; [@bib35]) throughout the brain and is primarily localized postsynaptically in dendrites and cell bodies ([@bib29]), indicating that enhancement of Ca^2+^ channel activity may specifically affect postsynaptic membrane excitability. In support of this notion, increased current amplitude and/or kinetic changes associated with Ca^2+^ current enhancement ([@bib82]; [@bib2]; [@bib22]; [@bib72]; [@bib71]; [@bib10]; [@bib47]) occur in different neurons and recombinant channels from the Ca~V~2 and Ca~V~3 families ([@bib28]; [@bib44]; [@bib10]; [@bib45]). In contrast, native or recombinant channels associated with Ca~V~β1b, Ca~V~β3, or Ca~V~β4 exhibit inhibition after similar stimulation ([@bib28]; [@bib35]; [@bib21]; [@bib22]; [@bib45]). Because Ca~V~β2 expression changes developmentally ([@bib73]) and with activity ([@bib29]), postsynaptic responses also may change over time. Patients with temporal lobe epilepsy exhibit increased postsynaptic Ca~V~β2 expression in damaged hippocampal regions. In contrast, patients that underwent surgical lesioning exhibit hippocampal Ca~V~β levels indistinguishable from control patients ([@bib29]), suggesting Ca~V~β2 expression is dynamically regulated by electrical activity. Moreover, it has been reported that although Ca~V~β expression appears necessary for surface expression of the N channel, once the channel reaches the cell surface, the Ca~V~β subunit can be exchanged ([@bib57]; [@bib24]). Thus, changes in current modulation caused by changes in Ca~V~β expression should not require a turnover of the entire channel complex.

Whether up-regulation of Ca~V~β2 is a response to counteract hyperexcitability or whether increased Ca~V~β2 levels contribute to excitotoxic neurodegeneration has not been determined. Nevertheless, these findings document in vivo plasticity of Ca~V~β2 expression. In the short term, palmitoyl acyl transferases dynamically regulate protein palmitoylation in hippocampal dendrites and cell bodies to control synaptic function ([@bib17]; [@bib20]). Pulse--chase experiments using tritiated palmitate indicate that palmitate turns over multiple times during the lifetime of most palmitoylated proteins, and recent experiments suggest that the pulse--chase experiments may underestimate the turnover rate by 15--20-fold as a result of reacylation of proteins by the radiolabeled palmitate within a cell (for review see [@bib1]). Thus, expression of Ca~V~β2a in postsynaptic regions should create a previously unrealized level of plasticity in which the response to a transmitter, acting on its G~q~PCR from moment to moment, may switch from inhibitory to excitatory depending on whether Ca~V~β2a\'s palmitoyl groups interact with Ca~V~2.2.

A role for multiple Ca~V~β isoforms in neurons
----------------------------------------------

In summary, we have shown that multiple Ca~V~β isoforms expressed in a recombinant system can recapitulate native N-current modulation by the slow pathway. Given the diversity of neuronal functions for calcium influx, there must be localized control of a channel\'s response to modulation. Our findings provide a previously unrecognized role for Ca~V~β subunits in the control of modulation and indicate a means by which G~q~PCR stimulation can simultaneously up- and down-regulate calcium flux at distinct sites within a single cell. Moreover, our experiments and analyses identify the sites that confer sensitivity to inhibition by AA as a likely site of plasticity.
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